^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tinurilimab (BAY1834942)

    i
    Other names: BAY 1834942, BAY-1834942, BAY1834942
    Associations

    News

    Trials
    Company:
    Bayer, German Cancer Research Center
    Drug class:
    CEACAM6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors. (PubMed, Target Oncol)
    Following study termination, the clinical development program for tinurilimab was discontinued permanently.
    P1 data • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    |
    tinurilimab (BAY1834942)
    8ms
    A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I-Labeled Tinurilimab. (PubMed, Adv Sci (Weinh))
    These results proves that 89Zr/131I-labeled tinurilimab facilitates the differential capacity of malignant pulmonary nodules and radioimmunotherapy of LUAD in preclinical models. Further clinical evaluation and translation of this CEACAM6-targeted theranostics may be significant help in diagnosis and treatment of LUAD.
    Journal • IO biomarker
    |
    CEACAM6 (CEA Cell Adhesion Molecule 6)
    |
    tinurilimab (BAY1834942)
    over3years
    T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction. (PubMed, Oncoimmunology)
    In summary, CEACAM6 blockade by BAY 1834942 reactivates the antitumor response of T cells. This warrants clinical evaluation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CEACAM6 (CEA Cell Adhesion Molecule 6) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    |
    tinurilimab (BAY1834942)
    over4years
    Study of BAY1834942 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2 (Interleukin 2) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    |
    tinurilimab (BAY1834942)
    over5years
    Study of BAY1834942 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting | N=156 --> 30 | Trial completion date: Dec 2021 --> Nov 2020 | Trial primary completion date: Jun 2021 --> Oct 2020
    Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2 (Interleukin 2) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    |
    tinurilimab (BAY1834942)
    over6years
    Study of BAY1834942 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Bayer | N=296 --> 156
    Clinical • Enrollment change
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2 (Interleukin 2) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    |
    tinurilimab (BAY1834942)
    7years
    Study of BAY1834942 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=296, Recruiting, Bayer | N=206 --> 296
    Clinical • Enrollment change • PD(L)-1 Biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2 (Interleukin 2) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    |
    tinurilimab (BAY1834942)
    over7years
    Study of BAY1834942 in Patients With Solid Tumors (clinicaltrials.gov)
    P1; N=206; Recruiting; Sponsor: Bayer
    New P1 trial
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2 (Interleukin 2) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    |
    tinurilimab (BAY1834942)